These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27377737)

  • 21. Clostridiodes difficile associated disease risk and proton pump inhibitors in critically ill children.
    Solana MJ; Bustinza A; López J; López-Herce J
    Enferm Infecc Microbiol Clin (Engl Ed); 2021 Mar; 39(3):160-161. PubMed ID: 32674905
    [No Abstract]   [Full Text] [Related]  

  • 22. The importance of quality appraisal in meta-analysis.
    Mahady SE; Webster AC
    Clin Gastroenterol Hepatol; 2012 Sep; 10(9):1057; author reply 1057-8. PubMed ID: 22503999
    [No Abstract]   [Full Text] [Related]  

  • 23. Proton pump inhibitors and risk for Clostridium difficile associated diarrhea.
    Biswal S
    Biomed J; 2014; 37(4):178-83. PubMed ID: 25116712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regional differences in Clostridium difficile infections in relation to fluoroquinolone and proton pump inhibitor use, Finland, 2008-2011.
    Kanerva M; Ollgren J; Voipio T; Mentula S; Lyytikäinen O
    Infect Dis (Lond); 2015 Aug; 47(8):530-5. PubMed ID: 25832317
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acid suppression therapy does not predispose to Clostridium difficile infection: the case of the potential bias.
    Novack L; Kogan S; Gimpelevich L; Howell M; Borer A; Kelly CP; Leffler DA; Novack V
    PLoS One; 2014; 9(10):e110790. PubMed ID: 25343667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burden of Clostridium difficile infection between 2010 and 2013: Trends and outcomes from an academic center in Eastern Europe.
    Kurti Z; Lovasz BD; Mandel MD; Csima Z; Golovics PA; Csako BD; Mohas A; Gönczi L; Gecse KB; Kiss LS; Szathmari M; Lakatos PL
    World J Gastroenterol; 2015 Jun; 21(21):6728-35. PubMed ID: 26074711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Editorial: PPIs and recurrent C. difficile infection: no association?
    Leontiadis GI
    Am J Gastroenterol; 2013 Nov; 108(11):1802-3. PubMed ID: 24192949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clostridium difficile infection in intestinal transplant recipients.
    Goldenberg V; Berbel A; Camargo JF; Simkins J
    Transpl Int; 2018 Jan; 31(1):116-117. PubMed ID: 28926130
    [No Abstract]   [Full Text] [Related]  

  • 29. Pathway to Prevention of Nosocomial Clostridium difficile Infection.
    Goldstein EJ; Johnson S; Maziade PJ; McFarland LV; Trick W; Dresser L; Millette M; Mazloum H; Low DE
    Clin Infect Dis; 2015 May; 60 Suppl 2():S148-58. PubMed ID: 25922401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton pump inhibitors are an independent risk factor for an increased length of hospital stay in patients with Clostridium difficile infection.
    Nachnani JS; Bulchandani D; Allen MJ
    Indian J Gastroenterol; 2008; 27(4):171-2. PubMed ID: 18974472
    [No Abstract]   [Full Text] [Related]  

  • 31. A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.
    Naggie S; Miller BA; Zuzak KB; Pence BW; Mayo AJ; Nicholson BP; Kutty PK; McDonald LC; Woods CW
    Am J Med; 2011 Mar; 124(3):276.e1-7. PubMed ID: 21396512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Acid Suppression Medication is Associated With Risk for C. difficile Infection in Infants and Children: A Population-based Study.
    Freedberg DE; Lamousé-Smith ES; Lightdale JR; Jin Z; Yang YX; Abrams JA
    Clin Infect Dis; 2015 Sep; 61(6):912-7. PubMed ID: 26060292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proton Pump Inhibitors and Clostridium difficile Infection.
    Goyal H; Katner H
    Am J Gastroenterol; 2017 May; 112(5):805. PubMed ID: 28469228
    [No Abstract]   [Full Text] [Related]  

  • 34. Intestinal Dysbiosis Secondary to Proton-Pump Inhibitor Use.
    Naito Y; Kashiwagi K; Takagi T; Andoh A; Inoue R
    Digestion; 2018; 97(2):195-204. PubMed ID: 29316555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overprescribing PPIs: Time for a hospital antacid policy on Clostridium difficile.
    Thachil J
    BMJ; 2008 Jan; 336(7636):109. PubMed ID: 18202039
    [No Abstract]   [Full Text] [Related]  

  • 36. Proton Pump Inhibitors and the Risk for Hospital-Acquired Clostridium difficile Infection.
    Barletta JF; El-Ibiary SY; Davis LE; Nguyen B; Raney CR
    Mayo Clin Proc; 2013 Oct; 88(10):1085-90. PubMed ID: 24012413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Proton Pump Inhibitors and Risk of Nosocomial Clostridium Difficile Infection in Hospitalized Elderly Adults.
    Depoorter L; Verhaegen J; Joosten E
    J Am Geriatr Soc; 2016 Mar; 64(3):667-9. PubMed ID: 27000353
    [No Abstract]   [Full Text] [Related]  

  • 38. Proton-pump inhibitor use before fecal microbiota transplant: A wonder drug, a necessary evil, or a needless prescription?
    Wong SH; Yu J
    J Gastroenterol Hepatol; 2020 Jun; 35(6):913-914. PubMed ID: 32537754
    [No Abstract]   [Full Text] [Related]  

  • 39. Are proton pump inhibitors associated with an increased risk of Clostridium difficile infection after considering confounding variables?
    Hughes K; Lalikian KA; Schwartz J; Turner RB
    J Hosp Infect; 2017 Apr; 95(4):445-446. PubMed ID: 27847127
    [No Abstract]   [Full Text] [Related]  

  • 40. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis.
    Deshpande A; Pant C; Pasupuleti V; Rolston DD; Jain A; Deshpande N; Thota P; Sferra TJ; Hernandez AV
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):225-33. PubMed ID: 22019794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.